News >

Novel Hormonal Agents Foster New Approaches in Nonmetastatic CRPC

Caroline Seymour
Published: Wednesday, Apr 01, 2020

William Kevin Kelly, DO, professor of medical oncology and urology at Thomas Jefferson University, and director of the Division of the Solid Tumor Oncology at Sidney Kimmel Cancer Center

William Kevin Kelly, DO

Nonmetastatic castration-resistant prostate cancer (M0CRPC) is a more recently defined clinical state of prostate cancer, for which several approved drugs are now available, explained William Kevin Kelly, DO, in a presentation during the 13th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication